
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September, 2020

Commission File Number: 001-39461

NANO-X IMAGING LTD

Communications Center
Neve Ilan, Israel 9085000
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

On September 22, 2020, NANO-X IMAGING LTD made a presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, a copy of which is furnished hereto as Exhibit 99.1.

The information in this Form 6-K, including the information set forth in Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Exhibit</u>
99.1	NANO-X IMAGING LTD's presentation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NANO-X IMAGING, INC.

By: /s/ Tal Shank

Name: Tal Shank

Title: Vice President of Corporate Development

Date: September 22, 2020

nanox

Dawn of early
detection
healthcare

 *Investor Presentation*
September 2020

Disclaimers

Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the Company or any director, employee, agent, or adviser of the Company. This presentation does not purport to be all inclusive or to contain all of the information about the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy the Company's securities, nor shall there be any sale of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Information Statement

Statements contained in this presentation concerning expectations, beliefs, plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact are "forward-looking statements." These statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "target," "project," "forecast," "seek," "will," "may," "should," "could," "would" or similar expressions. Although Nanox believes that the expectations and assumptions reflected in these statements are reasonable, these expectations or forecasts of future performance may not prove to be correct. Forward-looking statements are subject to many risks and uncertainties, and actual results may differ materially from the results discussed in forward-looking statements. The following are among the important factors that could cause actual results to differ materially from the forward-looking statements: risks related to Nanox's ability to successfully demonstrate the feasibility of its technology for commercial applications; Nanox's expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its X-Ray source technology and the Nanox.ARC from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; Nanox's ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; the market acceptance of the Nanox.ARC and the proposed pay-per-scan business model; Nanox's expectations regarding collaborations with third-parties and their potential benefits; Nanox's ability to conduct business globally; the impact of general economic conditions, general conditions in the medical technology and imaging industries; the impact of the COVID-19 pandemic on the Company's business operations; changes in the global and regional regulatory environments in the jurisdictions in which Nanox does or plans to do business; and market volatility, fluctuations in costs and changes to the competitive environment, among others. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Other risks and uncertainties of which Nanox is not currently aware may also affect these forward-looking statements. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and Nanox is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

These risks and uncertainties are described more fully under the caption "Risk Factors" in the Company's filings with the Securities and Exchange Commission. Other risks and uncertainties of which the Company is not currently aware may also affect Company's forward-looking statements. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

Market and Industry Data and Customer Information

This presentation has been prepared by Nanox and includes market data and other information from sources believed by us to be reliable. For example, industry and market data, including our own research, and surveys or industry publications and surveys as well as public information about our customers and discussion with them. Some data are also based on our good-faith estimates, which are derived from Nanox's review of internal sources as well as the other sources described above. Although Nanox believes these sources are reliable, Nanox has not independently verified the information is accurate and complete. As a result, you should be aware that market share, ranking and other similar data set forth in this presentation, and estimates and beliefs based on such data may not be reliable.

Nanox in a glance

The What

Nanox aims to build a global infrastructure for medical imaging

Utilizing innovative, patent protected and disruptive technology, Nanox can offer medical technology that expands access, resulting in better outcomes and lower costs.



Until today, technology was the barrier to medical imaging availability.

Nanox believes it has broken that barrier.

With global execution starting this year Nanox invites partners to join the potentially next revolution in preventive healthcare.

Unmet need

Massive deficit of medical imaging systems due to high system costs



2/3 of the world population has no access to medical imaging.

Weeks and months of wait times for radiology diagnostics results.

Game changing tech


A novel digital X-Ray source replacing an analog X-Ray that has been used for over 100 years enables significant cost reduction

A new breed of medical imaging infrastructure that can be deployed in mass due to significantly lower costs and small footprint coupled with a radiology services cloud platform



Upcoming Milestones

We are targeting several near term value catalysts such as FDA approval and commercialization



Disruptive business model

Executed contracts for 4,520 units pending regulatory approvals


Medical Screening as a Service (MSaaS) opens a recurring revenue model that has the potential to provide substantial revenues

Planning global mass deployment of 15,000 systems with a Pay-per-Scan subscription model

See slide 25 for full detail and assumptions

ILLUSTRATIVE MODEL

POTENTIAL ANNUAL RECURRING REVENUE ASSUMING THE 4,520 CONTRACTED UNITS ARE DEPLOYED AND OPERATIONAL



Strategic Shareholders



Exceptionally seasoned execution team

Healthcare and technology veterans from companies like GE, Philips, and highly successful, game-changing technology entrepreneurs

Preventive screening

4

OVERVIEW

EARLY DETECTION

THE BARRIER

BREAKING THROUGH

THE TECH

NANOX ARC

OUR PLAN

BUSINESS MODEL

DEPLOYMENTS

NANOX CLOUD


TEAM

SUMMARY

37

Early detection is key to preventive healthcare.

Treatable conditions, such as cancer, cardiovascular failures and others are often diagnosed too late.



Early detection remains theoretical

5

OVERVIEW

EARLY DETECTION

THE BARRIER

BREAKING THROUGH

THE TECH

NANOX ARC

OUR PLAN

BUSINESS MODEL

DEPLOYMENTS

NANOX CLOUD

TEAM

SUMMARY

37

2/3 of the world's population have no access to medical imaging

The majority of the remaining 1/3 suffer from weeks and months of wait time for access to medical scanners and diagnostic results.



OVERVIEW

EARLY DETECTION

THE BARRIER

BREAKING THROUGH

THE TECH

NANOX ARC

OUR PLAN

BUSINESS MODEL


DEPLOYMENTS

NANOX CLOUD

TEAM

SUMMARY

Medical imaging systems are too expensive and complex for mass deployment.



The key inhibitor

7

OVERVIEW

EARLY DETECTION

THE BARRIER

BREAKING THROUGH

THE TECH

NANOX ARC

OUR PLAN

BUSINESS MODEL

DEPLOYMENTS

NANOX CLOUD

TEAM

SUMMARY

37

**X-Ray source
technology has not
changed since its
discovery over 120
years ago**



Wilhelm Conrad Röntgen

The hot cathode

8

OVERVIEW

EARLY DETECTION

THE BARRIER

BREAKING THROUGH

THE TECH

NANOX ARC

OUR PLAN

BUSINESS MODEL


DEPLOYMENTS

NANOX CLOUD

TEAM

SUMMARY

37



Modern day X-Ray tube
Analog X-Ray source

Heats up a metal filament to **2,000° Celsius** to produce the electron streams necessary for X-Ray emission

Main contributor to high-cost of imaging systems

9


- OVERVIEW
- EARLY DETECTION
- THE BARRIER**
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY

37



The legacy analog X-Ray source

Requires extremely high-voltage, complex mechanics and special cooling to produce the electrons needed for X-Ray emission, resulting in an average \$150,000 cost for the source alone




The Nanox paradigm

10

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH**
- THE TECH
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY

37



Introducing the novel Nanox X-Ray source

11


- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY

37

Novel silicon-based, low voltage, nano-scale cold cathode

*Generating the electrons streams needed for
X-Ray via cold field-emission technology*

X-Ray Reimagined



Nanox MEMs X-Ray source

12

OVERVIEW

EARLY DETECTION

THE BARRIER

BREAKING THROUGH

THE TECH

NANOX ARC

OUR PLAN

BUSINESS MODEL

DEPLOYMENTS

NANOX CLOUD

TEAM


SUMMARY

37


- Technology originally developed by Sony and its partners to achieve a higher quality image for screens and monitors
- Sony invested substantial resources in the development of this technology for over a decade
- After acquiring the technology, our Japanese-Israeli team invested over 8 years developing a source for the medical imaging industry based on this technology
- Nanox-owned manufacturing facilities in Japan
- Signed agreement with SK Telecom for collaboration on a new Korean factory to increase Nanox MEMs production capacity
- Mature and optimized proprietary technology and production process with an exceptionally high-yield
- Strong IP portfolio with patents granted in USA, Israel, Japan and pending globally



NANOX CLEAN ROOM (JAPAN)



NANOX WAFER




Tech transformation

13

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH**
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY


37

From




One metal filament heated to 2,000° Celsius requiring special cooling and rotation mechanics

To



100 Million nano-cones field on a silicon chip emitting digitally controlled electron streams under low voltage



The Nanox tube

14

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH**
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY

37

Commercially available Digital X-Ray source



The Nanox Silicon
MEMs cold cathode



The Nanox tube

15

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH**
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY

37



LEGACY TUBE
\$150,000 average cost

Significantly smaller
Substantially more cost effective



NANOX
~\$100 estimated cost in
mass-production

Enabling a system-level quantum leap

16

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH**
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY


37

From



Analog
Large and complex
Costs millions of dollars

To



Digital
Small footprint
Costs tens of thousands of dollars




Footprint practicalities

17

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC**
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY

37




Clinical quality imaging

18

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC**
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY

37



kVp - Kilovolt Peak. kVp is the component that controls the X-Ray penetration strength and subsequently **QUALITY** of the X-Ray beam produced. It is also what controls the **CONTRAST** or **GRAY SCALE** in the produced X-Ray film. The Higher the **KVP** the **LOWER** the **CONTRAST**.

mAs - MilliAmps per Second. This parameter controls the **QUANTITY** or the **AMOUNT** of X-Ray photons produced. This is also what dictates the radiation dose. The higher the **mAs** the higher the radiation exposure.



Clinical quality imaging

19


- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC**
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY

37

3D Image Reconstruction



SHOULDER



NANOX X-Ray TUBE
40KV, 2.5MA




The Nanox.ARC 3D computerized tomosynthesis

20

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY

37

A new breed of medical imaging systems at a fraction of the cost potentially revolutionizing global availability



Regulatory clearance

21

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN**
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY

37

FDA

- We expect to take a multi-step approach to the regulatory clearance process:
 - Submitted a 510(K) application in January 2020 relating to a single digital X-ray source version of the Nanox.ARC
 - Received an additional information request in March 2020, which we responded to in September 2020
 - Plan to submit an additional 510(k) application with respect to the multiple-source Nanox.ARC which, if cleared, will be our commercial imaging system
 - We do not believe the Nanox X-ray source (the core component of the Nanox.ARC) will require a separate regulatory approval or clearance because the source is a Class 1 device, which is exempt from the 510(k) application process
- If cleared, we plan to deploy the first Nanox.ARC in the first half of 2021

CE and ROW

- CE submission and clearance expected in H1 2021
- Majority of ROW countries accept FDA and CE as a reference for local clearance
- Other countries will require separate submissions

ADVISORS

 Greenleaf Health

Daniel Schultz, MD, F.A.C.S.

Former Director of the Center for Devices and Radiological Health (CDRH) at FDA



Our plan


22

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN**
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY

37

Disrupt the imaging market with a global service infrastructure for medical imaging

- Increase significantly medical imaging availability
- Deploy 15,000 units globally by YE2024 subject to Company financing & regulatory clearance
- Invest CAPEX and own the systems
- Operate a Pay-per-Scan, MSaaS business model
- Generate substantial recurring revenue stream once fully deployed




Timeline and key milestones

23

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN**
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY

37




Addressable market

Expansion of the \$21 Billion global medical imaging market through shift from CAPEX to MSaaS model

24

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN**
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY

37



We do not compete over market share, we expand the total market

- We sell medical imaging **availability**
- We expect to provide systems to market segments existing X-Ray vendors don't target
- We target Urgent Care units (over 9,600 in the US alone), outpatient clinics, rural areas, countries with limited medical imaging availability (India, China, Africa...)
- We believe the CAPEX market of HMOs, hospitals and medical centers will migrate to an OPEX service-based model over time
- Nanox is pioneering this model today
- For certain medical imaging market participants, we plan to tailor our X-Ray source technology to their specific imaging systems and we expect to charge a one-time licensing fee upfront and receive recurring royalty payments for each system sold




Flexible business model to drive adoption

25

37

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL**
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY

MSaaS



Scans per day - LEGEND

- 7 - Minimum scans per day per system
- 20 - Nanox operational objective
- 60 - Estimated current global average

Pricing model & minimum annual service fee

- Pay-per-scan service business model
- Nanox covers CAPEX investment of systems and deployment
- **\$40 total cost per scan as a global average based on current contracts**
- **Nanox revenue \$14 (out of the \$40) per scan based on current contracts**
- Contracting regional service providers for marketing and operation of the service
- Current contracts provide a minimum annual service fee for 7 scans per day per system against regional exclusivity
- Total number of systems deployed may vary as per financing and final unit cost
- Price-per-scan will vary based on regional economics
- Minimum annual service fees will be backed by a standby letter of credit upon receipt of local regulatory approval



Contracted deployments

26

OVERVIEW

EARLY DETECTION

THE BARRIER

BREAKING THROUGH

THE TECH

NANOX ARC

OUR PLAN

BUSINESS MODEL

DEPLOYMENTS

NANOX CLOUD


TEAM

SUMMARY

37

Current contracts for deals - 5,150 units (Pending local regulatory approval)

- Australia, New Zealand, Norway - 1,000 units
- Taiwan, Singapore - 500 units
- Italy - 500 units
- Spain - 420 units
- Russia - 500 units
- Belarus - 100 units
- South Africa - 500 units
- Brazil - 1,000 units
- Mexico and Guatemala – 630 units



Minimum annual service fees

Nanox current contracts require a minimum annual service fee backed by a standby letter of credit upon receipt of local regulatory approval and satisfaction of all conditions precedent under each agreement

Strategic Collaboration Agreement - 5,500 units

- USA - 3,000 units
- Korea, Vietnam - 2,500 units

■ Closed pre-sale agreements ■ In negotiations

- Units of contracted pre-sale deals, with experienced service providers, are expected to be delivered from H1 2021
- Deliveries are conditioned upon acceptance test approval and local regulatory clearance in each region
- Active pipeline of additional countries aiming to join initial wave of deployment



Select Customer Profiles

27

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS**
- NANOX CLOUD
- TEAM
- SUMMARY

37

The Gateway Group

- One of Australia’s largest independent product distributors including health, wellness, medical supplies and devices
- Provides a wide range of products to over 20,000 locations with representation of medical device companies such as BrainsWay and others
- **Entered into an initial 3-year contract to deploy 1,000 Nanox Systems, consisting of the Nanox.ARC and Nanox.CLOUD, across Australia, New Zealand and Norway¹**
- **Anticipated \$27 million² minimum annual service fees to Nanox**



¹ Subject to regulatory approval and customer acceptance test

² Assumes 7 scans/day x 23 days/month x at \$14 per scan x 1,000 units deployed



Select Customer Profiles


28

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS**
- NANOX CLOUD
- TEAM
- SUMMARY

37

SPI Medical, S.A. de C.V. (Mexico)

- SPI Medical, S. A. de C.V. is a distributor of specialty pharma products and medical devices, operating with global leaders such as Abbott, Merck, Bayer and Eli Lilly, and medical imaging systems from Phillips, GE, Siemens, Planmed and Toshiba.
- Distributes to both the public and private sectors in Mexico and Guatemala.
- **Entered into an initial 7-year MSaaS agreement to distribute 630 Nanox Systems across Mexico and Guatemala¹**
- **Anticipated \$17 million² minimum annual service fees to Nanox**



SPI MEDICAL, S.A. DE C.V.

¹ Subject to regulatory approval and customer acceptance test

² Assumes 7 scans/day x 23 days/month x at \$14 per scan x 630 units deployed



Select Customer Profiles

29

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS**
- NANOX CLOUD
- TEAM
- SUMMARY

37

Promedica Bioelectronics s.r.l. (Italy)

- Promedica Bioelectronics s.r.l. has over 25 years of experience representing diagnostic imaging vendors such as Fujifilm, Siemens Medical Systems and GE Healthcare
- Also manages commercial strategic activities for multinational companies for the marketing of systems with MR-guided Focused Ultrasound (InSightec) and robotic systems for interventional radiology procedures (iSYS)
- **Entered into an initial 4-year MSaaS agreement to distribute 500 Nanox Systems across Italy¹**
- **Anticipated \$13.5 million² minimum annual service fees to Nanox**



¹ Subject to regulatory approval and customer acceptance test

² Assumes 7 scans/day x 23 days/month x at \$14 per scan x 500 units deployed



Select Customer Profiles

30
OVERVIEW
EARLY DETECTION
THE BARRIER
BREAKING THROUGH
THE TECH
NANOX ARC
OUR PLAN
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
TEAM
SUMMARY
37

APR Tecnologia Salud (Spain and Portugal)

- A distributor of diagnostic imaging equipment across Spain and Portugal
- Offers a full-service integrated approach to its customers comprising both equipment and service
- Expertise across broad range of OEM diagnostic equipment: CT, MRI, Radiology and Ultrasound
- **Entered into a 5-year MSaaS agreement for deployment of 420 Nanox Systems in Spain¹**
- **Anticipated \$11.4 million² minimum annual service fees to Nanox**

PRIVATE HEALTHCARE COMPANIES



PUBLIC SECTOR HEALTHCARE




¹ Subject to regulatory approval and customer acceptance test
² Assumes 7 scans/day x 23 days/month x at \$14 per scan x 420 units deployed

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY

Strategic collaboration with USARAD

- Over 250+ U.S. certified radiologists organization
- Providing online, remote radiology services across the U.S.
- 25% owned by Siemens Healthineers



- Working with one strategic partner for nationwide deployments instead of operating a large direct sales force
- Aiming to place 3,000 systems nationwide in the next 2 years
- Urgent care centers, primary care physicians, outpatient imaging centers, chiropractors, veterinarians and more
- Over 9,600 potential locations with unmet needs for medical imaging

Once cleared by the FDA we expect the Nanox.ARC imaging procedures will be covered by radiology CPT reimbursement codes

Strategic Alliance with SK Telecom

32

OVERVIEW

EARLY DETECTION

THE BARRIER

BREAKING THROUGH

THE TECH

NANOX ARC

OUR PLAN

BUSINESS MODEL

DEPLOYMENTS

NANOX CLOUD


TEAM

SUMMARY

37

Collaboration with SK Telecom announced June 2020

- SK Telecom has made two investments in Nanox:
 - \$5 million (June 2019)
 - \$20 million (June 2020)
- SK Telecom CEO Park Jung-ho joined the Nanox Board of Directors in August 2020
- Collaboration aims to deploy 2,500 Nanox Systems to clinics in South Korea and Vietnam
- Nanox to work toward establishing a wholly-owned subsidiary in Korea to support production of its MEMs X-ray source and leverage SK Telecom's expertise in semiconductors



The Nanox infrastructure management platform

Increasing availability of medical imaging systems solves only half of the problem


33

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD**
- TEAM
- SUMMARY

37

Purpose built proprietary radiology software platform streamlines operations and analytics

- Radiology diagnostics remain a significant bottleneck
- All Nanox.ARC systems will be connected to the **Nanox.CLOUD**
- A proprietary software platform designed to streamline the radiology diagnostics services and provide billing control



The Nanox.CLOUD

A central backbone of our imaging infrastructure that will provide the ability to scale with connectivity to robust services

34

OVERVIEW

EARLY DETECTION

THE BARRIER

BREAKING THROUGH

THE TECH

NANOX ARC

OUR PLAN

BUSINESS MODEL

DEPLOYMENTS


NANOX CLOUD

TEAM

SUMMARY

37

- Built ground-up with automation, privacy and security in mind
- Expected to be HIPPA and GDPR compliant
- Enables integration into medical systems via APIs
- Full administrative and billing services



Global partnerships

Nanox's cloud-based service will enable medical imaging services globally through its partnerships

35

OVERVIEW

EARLY DETECTION

THE BARRIER

BREAKING THROUGH

THE TECH

NANOX ARC

OUR PLAN

BUSINESS MODEL















DEPLOYMENTS


NANOX CLOUD

TEAM

SUMMARY

37

Strategic Partners	AI Diagnostics	Deployments
 <p>5G, MEMs manufacturing and APAC distribution</p>	 <p>Cancer detection</p>	 <p>United States</p>
 <p>Mammography OEM</p>	 <p>Stroke</p>	 <p>Taiwan, Singapore</p>
 <p>Manufacturing</p>	 <p>Chest & Head</p>	 <p>Italy</p>
	 <p>Mammography</p>	 <p>Russia, Belarus</p>
		 <p>Australia, Spain, New Zealand, Norway, Korea, Vietnam</p>
		 <p>Brazil, S.Africa</p>
		 <p>Mexica, Guatemala</p>



The team

A strong execution team with decades of relevant experience and proven track record of large-scale global projects, medical business expertise and bringing innovation to market

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM**
- SUMMARY



Ran Poliakine
 Founder & CEO
 The founder of the wireless charging industry, a serial entrepreneur focusing on global life-changing technologies and inventions in across multiple categories



Hitoshi Masuya
 Co-Founder and Head of NANOX Japan
 Originally co-invested in the Nanox project with Sony, now leading the Japan operation and a member of the board



Tal Shank
 SVP Corporate Development
 Over 15 years of international experience in commercial law and global business development. Tal has a substantial track record with private & public companies



Lydia Edwards
 President NANOX USA
 Lydia has spent the last 15 years in the medical field, focused on the sales of pulmonary and critical care solutions in the U.S. and international markets



Itzhak Maayan
 CFO
 Over 25 years of financial leadership roles in multi-national public companies including Perrigo, Cisco Systems, Xivia Technologies, and Elscint.



Yoel Raab
 CTO
 Ex-Intel and Orbotech Medical exec., Yoel has BSc. and MSc. degrees in Applied Physics and Microelectronics with a proven track record in product development



Anat Kaphan
 VP Product Marketing
 Ex Mazor Robotics, Philips Medical, and Lumentis, Anat has an extensive record with over 20 years of experience in medical systems development and marketing



Dr. Amir Ben Shalom
 CSO
 With over 250 patents granted & pending, Amir is a scientist, engineer, author, teacher and a renown expert in high-power, analog circuits and electro-optics



Bruce Edwards
 VP Business Development
 A serial entrepreneur in the medical and high-tech fields with an established track record in global marketing, sales, and strategic business development

Advisory board

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM**
- SUMMARY



Morry Blumenfeld
GE Healthcare



Prof. Geoffrey D. Rubin
Duke University



Prof. Norbert Pelc
Stanford University



Dr. Achille Mileto
UNIVERSITY OF WASHINGTON



Dr. Rafael Grossman
TED



Michael Jackman
GE Healthcare



Dr. Michael Yuz
USARAD



Prof. Peter Dawson
University College London, Hengzhong



Prof. Yong-woo
KANGDONG SAMKANG HOSPITAL



Thomas Deckle
IBM

Professional and involved advisory board of physicians, radiologists, business veterans and global opinion leaders. The Nanox advisory board is an integral part of our think-tank for product roadmap and strategy.

Financial Snapshot

38

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY**

Pro-forma cash*	Approx. \$244 mm
Debt	\$0

Expected use of cash	Amount (\$mm)
Manufacture of 15,000 Nanox.ARC units and investment in manufacturing capacities**	\$144 - \$194
The shipping, installation and deployment costs of the 15,000 Nanox Systems **	\$18 - \$30
Continued research and development of the Nanox.ARC, the development of the Nanox.CLOUD and for regulatory clearance in various regions	\$5 - \$9
The remaining funds, if any, to be used for research and development expenses, sales and marketing expenses, general and administrative expenses and general corporate purposes.	

* Cash and cash equivalents as of June 30, pro-forma for subsequent cross-over funding net proceeds, net IPO proceeds, including full exercise of the 15% underwriters' overallotment option

** To the extent the cost-per-unit of the Nanox.ARC is higher than we expected, we plan to reduce the number of units to be manufactured accordingly.


37

Key investment highlights

39

- OVERVIEW
- EARLY DETECTION
- THE BARRIER
- BREAKING THROUGH
- THE TECH
- NANOX ARC
- OUR PLAN
- BUSINESS MODEL
- DEPLOYMENTS
- NANOX CLOUD
- TEAM
- SUMMARY**

Nanox is a global company building a disruptive medical imaging infrastructure for early detection preventive healthcare



We are well positioned to serve an untapped market representing a significant part of the world's population


- Revolutionary model to transform and grow the already large medical imaging market
- Unique patented technology innovation
- We expect our technology and imaging as a service model will allow us to sell systems into markets and sites that do not have imaging systems and where our traditional imaging competitors cannot play
- Transformative business model disrupts by no longer focusing on high cost capital equipment, but instead, into a recurring revenue service model with software-like gross margins
- Business model allows company to focus on a handful of key deployment partners like radiology groups in the US vs thousands of hospitals and imaging centers, with a small focused clinical support team
- Anticipated 510(k) regulatory path for the Nanox.ARC in US and well-known ROW regulatory paths
- No reimbursement hurdles expected and stable codes familiar to all physicians
- Significant positive economic impact on radiology groups and individual practices

- **Nanox has a first mover advantage**
- **Developed a novel digital X-Ray source**
- **Global strategic partnerships with industry leaders**
- **Exceptional execution team**
- **A strong business model with contracts for 4,520 units that include a minimum annual service fee backed by a standby letter of credit upon receipt of regulatory approval**



37

ΠΑΝΟΧ



Thank you



Presenters



Lydia Edwards
President Nanox USA



Ran Poliakine
Founder & CEO



Itzhak Maayan
CFO



IU Kim
President SK Telecom
HK Office

